A New Paradigm Shift: Parts 1 and 2 (Pages 25-31)
DUE TO THE AGING OF THE population, most of our population will spend roughly half of their lives as presby-opes. The etiology of presby-opia has been poorly understood, and treatment options have failed to address the true issues with the disease, creating compro mises in vision that patients are eager to find a solution for, not expecting to have their daily lives affected. There is both an overlooked etiology regarding the mechanism of presbyopia in the medical community, as well as a lack of awareness in the presbyopic population in general. If we are to be successful in implementing presbyopic solutions that address the pathogenesis, onset, and progressive compounding of the clinical manifestations that accompany presbyopia, there must be an effort toward shifting the paradigm of education and awareness toward the real issues that provoke this elusive age-related disease.
Explore More Articles
Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
read moreARVO LIVE: AI revolution in ophthalmology
Ophthalmology Times® talked with AnnMarie Hipsley, DPT, PhD, about 3D finite element model used to understand more about the biomechanics of accommodation and dis-accommodation as it relates to functions for visual function as well as aqueous hydrodynamics at this year’s ARVO meeting.
read moreAce Vision Group Names Rob Kissling, MD, as Chief Medical Officer
Ace Vision Group announced that it has named Rob Kissling, MD, as Chief Medical Officer. Dr. Kissling has more than 20 years of experience integrating clinical development, medical strategy, and business planning to develop and commercialize devices and medicines for ophthalmology. His tenure has included companies such as Pharmacia, Pfizer, and Novartis. Most recently, he …
read more